Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
B-cell Non Hodgkin Lymphoma · Chronic Lymphocytic Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Contact: Study coordinator (HCC Clinical Trials Office) · hcc-clinical-trials@musc.edu · 843-792-9321Contact: Principal Investigator (Brian Hess, MD)
Study leads
Brian Hess, PHD
Principal Investigator
Medical University of South Carolina